Pfizer (PFE) and OPKO Health (OPK) announced that the U.S. FDA has approved NGENLA, a once-weekly, human growth hormone analog indicated for treatment of pediatric patients aged three years and older who have growth failure due to inadequate secretion of endogenous growth hormone. NGENLA is expected to become available for U.S. prescribing in August 2023.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PFE:
- Opko Health Soars on FDA Approval for Growth Hormone Therapy
- Cantor biotech/biopharma analysts hold analyst/industry conference call
- Cantor Fitzgerald biotech/biopharma to hold analyst/industry conference call
- Cantor Fitzgerald biotech/biopharma to hold a luncheon meeting
- Pfizer and Moderna: The Vaccine Boom is Over, and Shares are Plunging